转移性胃癌一线化疗疾病稳定后持续与停-走式S-1联合奥沙利铂的随机II期研究
本研究比较转移性胃癌患者经6周期SOX诱导化疗疾病控制后,持续SOX化疗与停-走式化疗(无化疗间期,进展后重新引入SOX)的疗效。持续组无进展生存期显著长于停-走组,但疾病控制持续时间和总生存期无显著差异,且持续组不良事件更多、生活质量更差。作者认为停-走策略可能是诱导化疗后转移性胃癌患者的合适选择。
要点
- 持续组中位PFS 10.5个月,停-走组7.2个月,HR 0.55(95%CI 0.37-0.81;P=0.002)。
- 两组中位OS分别为22.6个月与22.7个月,HR 0.78(95%CI 0.50-1.23;P=0.284),无显著差异。
- 持续组≥3级疲乏(28.8% vs 8.1%;P=0.003)和感觉神经病变(25.4% vs 9.7%;P=0.022)更多,生活质量利于停-走组。
核心结论
- 与停-走策略相比,维持化疗改善了PFS但未改善DDC和OS,并对生活质量有负面影响,提示停-走策略可能是转移性胃癌诱导化疗后的合适选择。
研究设计与样本
- 随机II期研究,比较转移性胃癌患者经6周期S-1/奥沙利铂(SOX)诱导化疗达到疾病控制后,持续SOX化疗与停-走式化疗的疗效。
- 共入组250例患者,247例参与诱导期,其中121例随机分配至持续组(n=59)或停-走组(n=62)。
- 主要终点为总生存期(OS)。
主要发现
- 持续组中位PFS显著长于停-走组:10.5个月 vs 7.2个月;HR 0.55(95%CI 0.37-0.81;P=0.002)。
- 两组中位DDC分别为10.5个月 vs 11.3个月,HR 0.92(95%CI 0.62-1.36;P=0.674),无显著差异。
- 两组中位OS分别为22.6个月 vs 22.7个月,HR 0.78(95%CI 0.50-1.23;P=0.284),无显著差异。
- 持续组≥3级疲乏发生率28.8% vs 停-走组8.1%(P=0.003);持续组≥3级感觉神经病变发生率25.4% vs 停-走组9.7%(P=0.022)。
- 生活质量包括全局健康状况、躯体/角色功能及其他症状评分显著利于停-走组。
临床怎么用
- 作者认为,对于转移性胃癌诱导化疗后的患者,停-走策略可能是合适的选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We compared continuous versus stop-and-go chemotherapy after disease stabilisation with induction chemotherapy in the first-line treatment of metastatic gastric cancer (MGC). METHODS: MGC patients who achieved disease control after 6 cycles of S-1/oxaliplatin (SOX) were randomised to receive either continuous SOX until progression (continuous arm) or to have a chemotherapy-free interval followed by SOX reintroduction at progression (stop-and-go arm). The primary end-point was overall survival (OS). RESULTS: Of the 250 patients enrolled, 247 participated in the induction phase. Of these, 121 patients were randomised to the continuous arm (n = 59) or the stop-and-go arm (n = 62). Progression-free survival (PFS) was significantly longer in the continuous arm than in the stop-and-go arm (10.5 versus 7.2 months; hazard ratio [HR] 0.55, 95% CI, 0.37-0.81; P = 0.002). Duration of disease control (DDC) and OS, however, were comparable between the two arms: median DDC, 10.5 versus 11.3 months, HR 0.92 (95% CI, 0.62-1.36; P = 0.674); median OS, 22.6 versus 22.7 months, HR 0.78 (95% CI, 0.50-1.23; P = 0.284). Adverse events including grade ≥3 fatigue (28.8% versus 8.1%; P = 0.003) and sensory neuropathy (25.4% versus 9.7%; P = 0.022) occurred more frequently in the continuous arm than in the stop-and-go arm. Quality of life (QOL) including global health status, physical/role functioning and other symptom scores significantly favoured the stop-and-go arm. CONCLUSION: Compared with the stop-and-go strategy, maintenance chemotherapy improved PFS but not DDC and OS and had a negative impact on QOL, suggesting the stop-and-go strategy may be an appropriate option in MGC patients following induction chemotherapy.
引用
- Park SR, Kim MJ, Nam BH, et al. A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer. Eur J Cancer. 2017. PMID: 28711577. doi:10.1016/j.ejca.2017.06.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。